Teduglutide is a glucagon‐like peptide 2 (GLP‐2) analogue that was approved by the United States Food and Drug Administration for the treatment of pediatric (>1 year) intestinal failure due to short bowel syndrome in 2019. The gene discussed is GCG; the disease is short bowel syndrome.